Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

Georgia officials halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1878.47 with a total volume of ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...